RESUMO
A 52-year-old woman underwent esophagogastroduodenoscopy after an abnormal medical examination, which revealed a mass lesion over half the circumference of the superior duodenal angulus. Immunostaining was diffusely positive for somatostatin, synaptophysin, and chromogranin A. A 3 cm-sized mass in the pancreaticoduodenal region and multiple nodular lesions of a few mm in both lobes of the liver were revealed by CT. The diagnosis is primary somatostatin-producing tumor of the duodenum with multiple liver metastases. She underwent gastric jejunal bypass for impaired transit. Afterwards hepatic infusion and systemic chemotherapy were continued, and 5 years passed without progression. When she stopped chemotherapy for 6 months, she started somatostatin analogue therapy because of the increase of the tumors. The tumors did not increase, and 20 years have passed since the start of treatment. We report a case of primary somatostatin-producing tumor of the duodenum with liver metastases that is still alive for a long period of time, with a review of the literature.
Assuntos
Neoplasias Duodenais , Neoplasias Hepáticas , Somatostatina , Somatostatinoma , Feminino , Humanos , Pessoa de Meia-Idade , Neoplasias Duodenais/tratamento farmacológico , Neoplasias Duodenais/patologia , Neoplasias Duodenais/cirurgia , Neoplasias Hepáticas/tratamento farmacológico , Neoplasias Hepáticas/secundário , Somatostatina/análogos & derivados , Somatostatina/análise , Somatostatina/uso terapêutico , Somatostatinoma/tratamento farmacológico , Somatostatinoma/secundário , Somatostatinoma/cirurgia , Resultado do TratamentoAssuntos
Neoplasias Duodenais/diagnóstico , Neoplasias Duodenais/patologia , Somatostatinoma/patologia , Somatostatinoma/secundário , Idoso , Biomarcadores Tumorais/análise , Colonoscopia , Neoplasias Duodenais/diagnóstico por imagem , Histocitoquímica , Humanos , Imuno-Histoquímica , Masculino , Radiografia Abdominal , Somatostatina/análise , Somatostatinoma/diagnóstico por imagem , Tomografia Computadorizada por Raios XAssuntos
Hemorragia Gastrointestinal/etiologia , Veia Porta , Somatostatinoma/diagnóstico por imagem , Neoplasias Vasculares/diagnóstico por imagem , Trombose Venosa/diagnóstico por imagem , Varizes Esofágicas e Gástricas/diagnóstico por imagem , Varizes Esofágicas e Gástricas/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/patologia , Veia Porta/diagnóstico por imagem , Radiografia , Somatostatinoma/complicações , Somatostatinoma/secundário , Neoplasias Vasculares/complicações , Neoplasias Vasculares/secundário , Trombose Venosa/etiologiaAssuntos
Neoplasias Duodenais/patologia , Neurofibromatose 1/patologia , Somatostatinoma/patologia , Diferenciação Celular , Procedimentos Cirúrgicos do Sistema Digestório , Neoplasias Duodenais/cirurgia , Humanos , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Neurofibromatose 1/cirurgia , Somatostatinoma/secundário , Somatostatinoma/cirurgia , Resultado do TratamentoAssuntos
Neoplasias Hepáticas/secundário , Neoplasias Pancreáticas/patologia , Adulto , Carcinoma de Células das Ilhotas Pancreáticas/secundário , Glucagonoma/secundário , Hepatectomia/métodos , Humanos , Neoplasias Hepáticas/cirurgia , Masculino , Pancreatectomia/métodos , Neoplasias Pancreáticas/cirurgia , Somatostatinoma/secundárioRESUMO
The clinical course of patients with metastatic neuroendocrine tumors is highly variable. While some patients experience an indolent clinical course over many years, other patients may rapidly succumb to their disease. Little is known about prognostic factors in these patients, making decisions regarding their management more difficult. We performed a retrospective analysis of 137 patients with metastatic neuroendocrine tumors referred to our institution for treatment. Potential prognostic factors were evaluated using multivariate survival analysis. The median overall survival of patients in our cohort was 6.0 years, although the range of survival times was broad (48 days to 23.4 years). Alkaline phosphatase levels above normal were predictive of shorter survival in both univariate and multivariate analysis. Elevated chromogranin A levels were also associated with shorter survival in univariate analysis; in a multivariate analysis, however, this correlation was no longer significant. There was no association between survival and gender, primary tumor site, or presence or absence of carcinoid syndrome. Elevated alkaline phosphatase is a robust adverse prognostic factor for survival in patients with metastatic neuroendocrine tumors and may be superior to chromogranin A in this setting. Close monitoring of alkaline phosphatase levels may be useful when considering initiation or changes of therapy in patients with metastatic neuroendocrine tumors.
Assuntos
Fosfatase Alcalina/sangue , Tumor Carcinoide/mortalidade , Neoplasias Intestinais/mortalidade , Neoplasias Hepáticas/mortalidade , Neoplasias Pancreáticas/mortalidade , Somatostatinoma/mortalidade , Análise de Variância , Bilirrubina/sangue , Tumor Carcinoide/secundário , Feminino , Humanos , Neoplasias Intestinais/patologia , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/patologia , Prognóstico , Modelos de Riscos Proporcionais , Estudos Retrospectivos , Somatostatinoma/secundário , Análise de SobrevidaRESUMO
A 72-year-old male was diagnosed as having a thoracic tumor in the left chest wall five years after resection of primary pancreatic somatostatinoma. The tumor was suggestive of metastasis to the chest wall or to the left lung from the previously resected somatostatinoma based on the abnormally elevated serum somatostatin level. Percutaneous biopsy confirmed that the lesion was an islet cell tumor and thoracotomy demonstrated metastasis to the left third rib without involvement of the left lung. Our case represents a rare documentation of somatostatinoma metastatic to the chest wall for which complete resection was performed.
Assuntos
Neoplasias Pancreáticas/patologia , Somatostatinoma/secundário , Neoplasias Torácicas/secundário , Neoplasias Torácicas/cirurgia , Parede Torácica , Idoso , Humanos , Masculino , Neoplasias Pancreáticas/cirurgia , Somatostatinoma/patologia , Somatostatinoma/cirurgia , Neoplasias Torácicas/patologia , Parede Torácica/cirurgia , Tomografia Computadorizada por Raios XAssuntos
Tumores do Estroma Gastrointestinal/complicações , Neoplasias Primárias Múltiplas , Neurofibromatose 1/complicações , Neoplasias Pancreáticas/complicações , Somatostatinoma/complicações , Tumores do Estroma Gastrointestinal/metabolismo , Humanos , Imuno-Histoquímica , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/diagnóstico , Neoplasias Pancreáticas/patologia , Somatostatinoma/diagnóstico , Somatostatinoma/secundárioRESUMO
Somatostatinomas are rare functioning neoplasms usually arising in the pancreas and duodenum. We report a case of somatostatinoma in a 42-year-old male with neither neurofibromatosis nor somatostatinoma syndrome. A large tumor in the descending duodenum had given rise to multiple lymph node metastases. An additional 31 duodenal somatostatinoma cases were also reviewed. Most originated in the descending part of the duodenum, with the ampulla and peri-ampullary area as the most common sites (60%). Frequent manifestations were abdominal pain (25%), jaundice (25%), or cholelithiasis (19%), the latter two reflecting obstruction of the bile duct by tumors. Only two cases showed a possible somatostatinoma syndrome (6%). The tumors with metastases, lymph nodes (10) and liver (2), were significantly larger than average than those without (2.91 +/- 1.49 cm vs 1.36 +/- 0.71 cm, P < 0.05). With a cut-off point of 2.0 cm, diagnostic accuracy for metastasis was 77.78% with 87.50% specificity and 63.64% sensitivity. The smallest tumor with metastases was 0.8 cm and the largest without metastases was 3.0 cm. These results indicate that duodenal somatostatinomas are malignant by nature and the risk of metastasis significantly increases with tumors larger than 2.0 cm.
Assuntos
Neoplasias Duodenais/patologia , Neoplasias Hepáticas/secundário , Metástase Linfática/patologia , Somatostatinoma/secundário , Adulto , Biomarcadores Tumorais/análise , Grânulos Citoplasmáticos/ultraestrutura , Neoplasias Duodenais/diagnóstico por imagem , Neoplasias Duodenais/cirurgia , Seguimentos , Humanos , Técnicas Imunoenzimáticas , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/cirurgia , Linfonodos/patologia , Masculino , Microscopia Imunoeletrônica , Sistemas Neurossecretores/ultraestrutura , Somatostatina/análise , Somatostatinoma/diagnóstico por imagem , Somatostatinoma/cirurgia , Tomografia Computadorizada por Raios XRESUMO
BACKGROUND/AIMS: The endocrine tumors of the pancreas are rare diseases and there is no established standard therapy for the liver metastasis of pancreatic endocrine tumors. In this study, the therapy for the pancreatic endocrine tumors was evaluated. METHODOLOGY: The endocrine pancreas tumors of 13 patients had been surgically treated. All primary tumors were completely resected. The liver metastasis was recognized in 4 patients. Partial resection of the liver was performed in 2 patients. Lipiodol-transcatheter arterial embolization was performed for synchronous unresectable liver metastases in the other 2 patients. RESULTS: The patients with no liver metastases survived without recurrence (max: 18.8 yr; mean follow-up: 9.2 yr). The patient with resected synchronous solitary liver metastasis died of recurrent multiple liver metastases 5 months after surgery. The other patient with the metachronous liver metastasis completely resected survived 13.9 years. In the 2 patients with unresectable numerous liver metastases, after lipiodol-transcatheter arterial embolization, tumor necrosis rate was more than 90% in both cases and serum gastrin level was normalized. CONCLUSIONS: Complete resection of liver metastasis is favorable, whereas lipiodol-transcatheter arterial embolization is effective for unresectable liver metastases from pancreatic endocrine tumors as palliation. Complete resection of the primary site is recommended even in the cases with unresectable numerous liver metastases.
Assuntos
Gastrinoma/secundário , Insulinoma/secundário , Neoplasias Hepáticas/secundário , Pancreatectomia/métodos , Neoplasias Pancreáticas/cirurgia , Somatostatinoma/secundário , Adulto , Idoso , Angiografia , Feminino , Seguimentos , Gastrinoma/diagnóstico por imagem , Gastrinoma/mortalidade , Gastrinoma/cirurgia , Hepatectomia , Humanos , Insulinoma/diagnóstico por imagem , Insulinoma/mortalidade , Insulinoma/cirurgia , Fígado/irrigação sanguínea , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/mortalidade , Neoplasias Hepáticas/cirurgia , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/mortalidade , Reoperação , Somatostatinoma/diagnóstico por imagem , Somatostatinoma/mortalidade , Somatostatinoma/cirurgia , Taxa de Sobrevida , Tomografia Computadorizada por Raios XAssuntos
Linfoma de Zona Marginal Tipo Células B/patologia , Neoplasias Primárias Múltiplas/patologia , Neoplasias Pancreáticas/patologia , Somatostatina/sangue , Somatostatinoma/secundário , Neoplasias Gástricas/patologia , Adulto , Progressão da Doença , Evolução Fatal , Feminino , Humanos , Linfoma de Zona Marginal Tipo Células B/sangue , Neoplasias Primárias Múltiplas/sangue , Neoplasias Pancreáticas/sangue , Somatostatinoma/sangue , Neoplasias Gástricas/sangueRESUMO
BACKGROUND: The development of endocrine tumours of the duodenopancreatic area (ETDP) is thought to be slow, but their natural history is not well known. The aim of this study was to determine the factors that influence survival of patients with ETDP. PATIENTS/METHODS: Eighty two patients with ETDP (44 non-functioning tumours, 23 gastrinomas, seven calcitonin-secreting tumours, four glucagonomas, three insulinomas, one somatostatinoma) followed from October 1991 to June 1997 were included in the study. The following factors were investigated: primary tumour size, hormonal clinical syndrome, liver metastases, lymph node metastases, extranodular/extrahepatic metastases, progression of liver metastases, local invasion, complete resection of the primary tumour, and degree of tumoral differentiation. The prognostic significance of these factors was investigated by uni- and multi-variate analysis. RESULTS: Twenty eight patients (34%) died within a median of 17 months (range 1-110) from diagnosis. Liver metastases (p = 0.001), lymph node metastases (p = 0.001), progression of liver metastases (p < 0.00001), lack of complete resection of the primary tumour (p = 0.001), extranodular/extrahepatic metastases (p = 0.001), local invasion (p = 0.001), primary tumour size > or = 3 cm (p = 0.001), non-functioning tumours (p = 0.02), and poor tumoral differentiation (p = 0.006) were associated with an unfavourable outcome by univariate analysis. Multivariate analysis identified only liver metastases (risk ratio (RR) = 8.3; p < 0.0001), poor tumoral cell differentiation (RR = 8.1; p = 0.0001), and lack of complete resection of the primary tumour (RR = 4.8; p = 0.0007) as independent risk factors. Five year survival rates were 40 and 100% in patients with and without liver metastases, 85 and 42% in patients with and without complete resection of primary tumour, and 17 and 71% in patients with poor and good tumour cell differentiation respectively. CONCLUSION: Liver metastases are a major prognostic factor in patients with ETDP. Progression of liver metastases is also an important factor which must be taken into account when deciding on the therapeutic approach. The only other independent prognostic factors are tumoral cell differentiation and complete resection of the primary tumour.
Assuntos
Adenoma de Células das Ilhotas Pancreáticas/mortalidade , Neoplasias Hepáticas/secundário , Neoplasias Pancreáticas/mortalidade , Somatostatinoma/mortalidade , Adenoma de Células das Ilhotas Pancreáticas/cirurgia , Adulto , Idoso , Calcitonina/metabolismo , Feminino , Seguimentos , Humanos , Neoplasias Hepáticas/mortalidade , Metástase Linfática , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/cirurgia , Prognóstico , Estudos Retrospectivos , Risco , Somatostatinoma/secundário , Somatostatinoma/cirurgia , Taxa de Sobrevida , Resultado do TratamentoRESUMO
This article describes the visualization of a pancreatic somatostatinoma and liver metastases using 111In-pentetreotide imaging in a patient with somatostatinoma syndrome. A 61-yr-old woman with gallbladder stones, diabetes, weight loss, diarrhea and steatorrhea, immunohistochemical diagnosis of somatostatinoma (liver biopsy) and high plasma values of somatostatin was studied by somatostatin receptor scintigraphy. Six sites of focal abnormal 111In-pentetreotide hyperfixation were found: three in the liver and three in the pancreatic area. This case report demonstrates that in vivo detection of somatostatinoma with somatostatin receptor imaging is possible in the presence of high levels of circulating somatostatin, suggesting that receptor downregulation has not occurred.
Assuntos
Radioisótopos de Índio , Octreotida/análogos & derivados , Neoplasias Pancreáticas/diagnóstico por imagem , Ácido Pentético/análogos & derivados , Compostos Radiofarmacêuticos , Receptores de Somatostatina/análise , Somatostatinoma/diagnóstico por imagem , Feminino , Humanos , Neoplasias Hepáticas/diagnóstico por imagem , Neoplasias Hepáticas/secundário , Pessoa de Meia-Idade , Neoplasias Pancreáticas/patologia , Somatostatinoma/secundário , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
UNLABELLED: Early symptoms of malignant somatostatinoma with dyspeptic complaints, moderate diabetes mellitus and cholecystolithiasis are the reason of primary treatment of these patients by surgeons. CASE REPORT: In a 34-year old patient with typical anamnesis of cholecystitis and moderate diabetes mellitus liver metastases were seen during laparotomy. In the beginning the metastases were mistaken for hepatocellular carcinoma histologically. There was no deterioration until June 1988 when a high-grade stenosis of the duodenum has developed. Now a malignant somatostatinoma was diagnosed histologically and confirmed by immunohistology. Somatostatinomas are generally diagnosed by repeated measures of increased plasma SLI associated with decreased insulin, glucagon, pancreatic-polypeptide (PP) and vasoactive-intestinal-peptide (VIP). In normally or moderately increased plasma SLI concentrations provocation with tolbutamid may be helpful. Treatment should remove most of the tumor by surgical intervention, while chemotherapy must be less pronounced.
Assuntos
Adenoma de Células das Ilhotas Pancreáticas/secundário , Neoplasias Duodenais/diagnóstico , Neoplasias Hepáticas/secundário , Somatostatinoma/secundário , Adulto , Diagnóstico Diferencial , Neoplasias Duodenais/patologia , Duodeno/patologia , Seguimentos , Hormônios Ectópicos/sangue , Humanos , Imuno-Histoquímica , Fígado/patologia , Neoplasias Hepáticas/diagnóstico , Linfonodos/patologia , Metástase Linfática , Masculino , Síndromes Endócrinas Paraneoplásicas/diagnóstico , Somatostatina/sangue , Somatostatinoma/diagnóstico , Somatostatinoma/patologiaRESUMO
High circulating levels of somatostatin (SRIF) were detected in a patient with a metastatic tumour after development of diabetic ketoacidosis (DKA). Fasting insulin and C-peptide levels were markedly suppressed, but plasma glucagon was not suppressed below normal. Progressive cachexia ensued; at autopsy a poorly differentiated non-small cell neuroendocrine carcinoma metastatic to liver was found. Small gallstones were noted. Electron microscopy of tumour tissue showed neurosecretory granules and tonofilament bundles. Immunohistochemical staining of tumour cells was diffusely positive for carcinoembryonic antigen, bombesin-like immunoreactivity, and calcitonin with focal immunoreactivity for SRIF, serotonin, neuron-specific enolase, chromogranin, and epithelial membrane antigen. Column chromatography of plasma and tumour extract revealed five or more peaks of material with SRIF-like immunoreactivity (SRIF-LI): predominantly SRIF-28 and intermediates in tumour extract, and SRIF-14 and an intermediate between SRIF-28 and SRIF-14 in plasma, DKA in this case of somatostatinoma syndrome may reflect differential effects of tumour production of larger molecular weight SRIF forms on insulin and glucagon secretion.
Assuntos
Adenoma de Células das Ilhotas Pancreáticas/complicações , Cetoacidose Diabética/etiologia , Neoplasias Pulmonares/complicações , Somatostatinoma/complicações , Idoso , Humanos , Neoplasias Hepáticas/patologia , Neoplasias Hepáticas/secundário , Neoplasias Pulmonares/patologia , Masculino , Somatostatinoma/patologia , Somatostatinoma/secundárioAssuntos
Adenoma de Células das Ilhotas Pancreáticas/secundário , Neoplasias Hepáticas/secundário , Neoplasias Pancreáticas , Somatostatinoma/secundário , Feminino , Humanos , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/ultraestrutura , Microscopia Eletrônica , Pessoa de Meia-Idade , Somatostatina/análise , Somatostatinoma/metabolismo , Somatostatinoma/ultraestruturaRESUMO
Somatostatinoma is the rarest of the pancreatic islet cell tumors with only eight previously reported cases. We report a recent case in a 62-year-old man including CT findings and 1 year follow-up.
Assuntos
Adenoma de Células das Ilhotas Pancreáticas/diagnóstico por imagem , Neoplasias Pancreáticas/diagnóstico por imagem , Somatostatinoma/diagnóstico por imagem , Tomografia Computadorizada por Raios X , Terapia Combinada , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Pancreáticas/cirurgia , Somatostatinoma/secundário , Somatostatinoma/cirurgiaRESUMO
A case of somatostatinoma syndrome in a 30-year-old woman is presented. Basal levels of growth hormone and of pancreatic and gastric hormones were reduced and the response of growth hormone, insulin and C-peptide to stimuli such as arginine, glucose, glibenclamide and calcium was virtually abolished. Similarly, gastric acid secretion, pancreatic exocrine function and intestinal absorption were significantly reduced. On the other hand, basal and stimulated levels of adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) were within the normal range. Plasma somatostatin-like immunoreactivity was increased to 600-2,000 pg/ml (normal: 88-140 pg/ml). Immunocytochemical studies demonstrated the presence of somatostatin immunoreactive material in the primary tumour in the head of the pancreas and in the liver metastases. In spite of two courses of chemotherapy with streptozotocin and 5-fluorouracil the patient died due to liver failure 5 months after the first admission to hospital.